AUTOMOTIVE FUEL DIESEL OIL En590 SPECIFICATION GASOIL 10 GOST � 52368-2005 (�?N 590:2004), CLASS 1, TYPE III Unit Description Value Density at 15 degr. kg/m3 max. 845 Cetane index min. 49 Kinematic viscosity at 20 Co mm2 (cSt) Min. 2.0 / Max. 4.5 Acidity, mg KOH for 100 cm2 of fuel, max. 10 Ash content, %, max. 0.01 Sulphur content, mg/kg, max. 10 Hydrogen sulphide content Absent Copper plate test Passed Water soluble acids & alkalis Passed Content of mechanical impurities Passed Water content mg/kg 200 Flash point determined in a closed cup, Cáµ? Min. 55 Solidification temperature, Cáµ?, Max. Cloud temperature, Cáµ?, Max. 16 Filterability temperature Cáµ? -27 Fat acid methyl ether content (FAME), % 5 Bacterial contamination (IP 385), CFU /litre, Max. 1,000 Quantity: 100,000 MT for Month's CIF, Singapure
10ppm
Diesel d1.
Diesel.
En590 10ppm Diesel.
Diesel En590 10ppm.
Biodiesel B2.
icumsa 45 sugar, en590 diesel.
Diesel Engine.
Diesel engine spare parts.
Household, kitcheware, (face puff, loofah, mop, bath shelf, kitchen knife, pan, ete.).
En590 fuel diesel.
D2 fuel and jet a1.
En590 10ppm.
Diesel fuel en590 ulsd 10 ppm.
Jet a1, diesel virgin fuel oil d6.
Diesel en590 10ppm.
En590 10ppm Diesel Gas Oil..
EN590 diesel LNG and LCO.
DiaPlexQ Novel Coronavirus (2019-nCoV) Detection Kit Real-Time OneStep RT-PCR based assay system for detection of SARS-CoV-2 [Product Approval] U.S FDA EUA, Health Canada IO, CE-IVD marked The DiaPlexQ Novel Coronavirus (2019-nCoV) Detection Kit is a real-time reverse transcriptase (RT)-PCR test intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal swabs, oropharyngeal (throat) swabs, anterior nasal swabs, mid-turbinate nasal swabs, nasal aspirates, nasal washes, bronchoalveolar lavage (BAL) fluid and sputum from individuals suspected of COVID-19 by their healthcare provider. Results are for the identification of SARS-CoV-2 RNA. The SARS-CoV-2 RNA is generally detectable in respiratory specimens during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. The agent detected may not be the definite cause of disease. Positive results do not rule out bacterial infection or co-infection with other viruses. Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information. The DiaPlexQ Novel Coronavirus (2019-nCoV) Detection Kit is intended for use by qualified clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and in vitro diagnostic procedures.
